OTCMKTS:ASPHF Ascentage Pharma Group International (ASPHF) Stock Price, News & Analysis $4.53 0.00 (0.00%) As of 09/11/2026 Add Compare Share Share Stock Analysis Stock AnalysisChartNews and Trends About Ascentage Pharma Group International Stock (OTCMKTS:ASPHF) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get ASPHF alerts:Sign Up Key Stats Today's Range$4.53▼$4.5350-Day Range$4.53▼$4.5352-Week Range$4.53▼$5.05VolumeN/AAverage Volume100 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Ascentage Pharma Group International (OTCMKTS:ASPHF) is a clinical-stage biopharmaceutical company headquartered in Beijing, China, with a strategic presence in the United States. The company focuses on the discovery and development of targeted small-molecule therapies that modulate programmed cell death, leveraging a deep understanding of the Bcl-2 family of proteins. Ascentage’s core activities center on the research and development of apoptosis regulators, including both Bcl-2 selective and dual Bcl-2/Bcl-xL inhibitors. Its diverse pipeline comprises several compounds in various stages of clinical and preclinical evaluation, addressing both hematological malignancies and solid tumors. The company’s R&D operations integrate proprietary chemistry platforms with translational biology to accelerate the progression of novel candidates through global regulatory pathways. The company serves markets across Greater China, North America, and Singapore, collaborating with contract research organizations and academic institutions worldwide. Through partnerships and strategic alliances, Ascentage aims to expand its clinical footprint and optimize trial execution, particularly for oncology indications with significant unmet medical needs. Founded in 2010 by a team of life science researchers, Ascentage has grown under a management team of industry veterans with extensive experience in drug discovery and development. This leadership combines academic insights with pharmaceutical expertise to drive innovation and establish the company as a global player in oncology therapeutics.AI Generated. May Contain Errors. Read More Receive ASPHF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ascentage Pharma Group International and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ASPHF Stock News HeadlinesJeet Mukherjee Initiates Buy on Ascentage Pharma, Citing 2027 NRDL Lisaftoclax Catalyst, Late‑Stage Pipeline Readouts, and Cash Runway Through 2027August 21, 2026 | tipranks.comAscentage Pharma Lifts Revenue, Deepens Losses as U.S. Push and BTK Degrader Trials AdvanceAugust 19, 2026 | tipranks.comThe dollar reset no one told you aboutPorter Stansberry says a dollar reset is underway - one that has happened only once before in America's 250-year history, back in 1974 with a secret Saudi deal that reshaped an entire generation's wealth. Today, a landmark treaty called Pax Silica - signed by 13 nations in December 2025 and barely covered in the press - is at the center of what Fortune calls 'the biggest change to the world's relationship with the dollar' in a generation. The stocks to buy, the assets to avoid, and the moves to consider are outlined in Stansberry's new briefing.September 12 at 1:00 AM | Porter & Company (Ad)Ascentage Pharma Corrects Timing for August 19, 2026 Interim Results WebcastAugust 13, 2026 | tipranks.comAscentage Pharma Sets Board Meeting to Approve 2026 Interim ResultsAugust 5, 2026 | tipranks.comAscentage Pharma Strengthens Global Commercial Push With Senior Executive HiresAugust 2, 2026 | tipranks.comAscentage Pharma Advances Phase III Oral Combo in CLL: What Investors Should WatchJuly 28, 2026 | tipranks.comAscentage Pharma CEO Dajun Yang Ranked Among Top Small-Molecule Leaders in 2026 Power ListJuly 27, 2026 | tipranks.comSee More Headlines ASPHF Stock Analysis - Frequently Asked Questions How have ASPHF shares performed this year? Ascentage Pharma Group International's stock was trading at $8.48 at the beginning of the year. Since then, ASPHF shares have decreased by 46.6% and is now trading at $4.53. How do I buy shares of Ascentage Pharma Group International? Shares of ASPHF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolOTCMKTS:ASPHF CIKN/A Webwww.ascentagepharma.com Phone86-512-8555-7777FaxN/AEmployees565Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 7 Best Space Stocks to Own in 2026The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free Report This page (OTCMKTS:ASPHF) was last updated on 9/12/2026 by MarketBeat.com Staff. From Our PartnersBezos… DOOMEDA single FCC filing hints Elon Musk is planning his biggest project yet - bigger than Tesla, SpaceX, and X com...Paradigm Press | SponsoredShocking AI prediction from the “Billionaire Whisperer"Marc Chaikin's Power Gauge system flagged Micron before it soared 970 percent, Celestica before a 6,600 percen...Chaikin Analytics | SponsoredThey didn't warn anyone in 1971. This time someone is warning you.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredThis 38 Dollar Fund Holds Every Major AI Stock and Pays WeeklyThe biggest AI stocks like Nvidia, CrowdStrike, and Palantir now trade for hundreds of dollars a share. One fu...Investors Alley | SponsoredWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | SponsoredHow options let you do more with less capitalWould you rather spend $5,000 buying 100 shares of a $50 stock, or control those same 100 shares for a fractio...Base Camp Trading | SponsoredThe retirement income that answers “yes” when everything else says noTodd Phillips has spent 30 years studying safe-money income. He says most so-called income sources fail one te...Eagle Publishing | SponsoredMy ‘one day’ retirement secretTradeSmith's AI research team, backed by a $17 million investment and led by a former NSA codebreaker, built a...TradeSmith | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ascentage Pharma Group International Please log in to your account or sign up in order to add this asset to your watchlist. Share Ascentage Pharma Group International With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.